美农生物
(301156)
| 流通市值：12.40亿 | | | 总市值：19.29亿 |
| 流通股本：1.18亿 | | | 总股本：1.84亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 539,862,722.84 | 327,552,727.24 | 159,023,381.03 | 561,265,718.82 |
| 营业收入 | 539,862,722.84 | 327,552,727.24 | 159,023,381.03 | 561,265,718.82 |
| 利息收入 | 0 | - | - | - |
| 已赚保费 | 0 | - | - | - |
| 手续费及佣金收入 | 0 | - | - | - |
| 二、营业总成本 | 503,581,611.85 | 299,318,883.41 | 138,733,565.05 | 504,072,553.74 |
| 营业成本 | 397,474,688.67 | 230,837,907.14 | 108,963,866.12 | 389,275,741.83 |
| 利息支出 | 0 | - | 0 | 0 |
| 手续费及佣金支出 | 0 | - | 0 | 0 |
| 退保金 | 0 | - | 0 | 0 |
| 赔付支出净额 | 0 | - | 0 | 0 |
| 提取保险合同准备金净额 | 0 | - | 0 | 0 |
| 保单红利支出 | 0 | - | 0 | 0 |
| 分保费用 | 0 | - | 0 | 0 |
| 税金及附加 | 3,528,691.95 | 2,405,210.65 | 1,254,827.71 | 4,096,371.7 |
| 销售费用 | 42,325,551.5 | 27,341,094.68 | 11,396,089.66 | 46,578,390.25 |
| 管理费用 | 33,959,705.03 | 21,945,827.76 | 10,183,876.28 | 39,482,975.73 |
| 研发费用 | 20,915,885.83 | 13,014,129.87 | 5,302,166.52 | 24,839,817.14 |
| 财务费用 | 5,377,088.87 | 3,774,713.31 | 1,632,738.76 | -200,742.91 |
| 其中:利息费用 | 5,399.97 | 3,381.56 | 1,681.64 | 6,952.7 |
| 其中:利息收入 | 739,270.06 | 510,843.54 | 271,981.98 | 1,731,904.17 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -222,760.51 | -588,166.42 | -63,258.8 | -224,366.52 |
| 加:投资收益 | 1,825,240.82 | 762,969.21 | 695,211.86 | 2,547,873.06 |
| 净敞口套期收益 | 0 | - | 0 | 0 |
| 汇兑收益 | 0 | - | 0 | 0 |
| 资产处置收益 | -93,522.32 | -97,956.57 | 0 | -3,262.16 |
| 资产减值损失(新) | -5,864,572.46 | -9,081,043.75 | -7,040,133.88 | -2,869,343.94 |
| 信用减值损失(新) | -2,184,570.07 | -1,141,519.59 | -306,052.86 | -1,032,593.87 |
| 其他收益 | 2,182,112.14 | 1,467,113.04 | 790,363.24 | 4,970,837.18 |
| 四、营业利润 | 31,923,038.59 | 19,555,239.75 | 14,365,945.54 | 60,582,308.83 |
| 加:营业外收入 | 132,506.95 | 68,237.95 | 0.87 | 444,858.23 |
| 减:营业外支出 | 168,242.56 | 121,974.38 | 3,418.8 | 257,704.96 |
| 五、利润总额 | 31,887,302.98 | 19,501,503.32 | 14,362,527.61 | 60,769,462.1 |
| 减:所得税费用 | 3,968,283.58 | 1,440,494.34 | 910,264.4 | 5,958,926.3 |
| 六、净利润 | 27,919,019.4 | 18,061,008.98 | 13,452,263.21 | 54,810,535.8 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 27,919,019.4 | 18,061,008.98 | 13,452,263.21 | 54,810,535.8 |
| 终止经营净利润 | 0 | - | - | - |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 27,919,019.4 | 18,061,008.98 | 13,452,263.21 | 54,810,535.8 |
| 少数股东损益 | 0 | - | - | - |
| 扣除非经常损益后的净利润 | 26,598,057.68 | 17,764,878.8 | 13,091,469.22 | 51,350,779.77 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.15 | 0.1 | 0.1 | 0.39 |
| (二)稀释每股收益 | 0.15 | 0.1 | 0.1 | 0.39 |
| 八、其他综合收益 | 0 | - | - | - |
| 归属于母公司股东的其他综合收益 | 0 | - | - | - |
| 九、综合收益总额 | 27,919,019.4 | 18,061,008.98 | 13,452,263.21 | 54,810,535.8 |
| 归属于母公司股东的综合收益总额 | 27,919,019.4 | 18,061,008.98 | 13,452,263.21 | 54,810,535.8 |
| 归属于少数股东的综合收益总额 | 0 | - | - | - |
| 公告日期 | 2026-10-29 | 2026-08-27 | 2026-04-28 | 2026-04-28 |
| 审计意见(境内) | | | | 标准无保留意见 |